304 related articles for article (PubMed ID: 27662011)
1. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Hart C; Klatt S; Barop J; Müller G; Schelker R; Holler E; Huber E; Herr W; Grassinger J
Haematologica; 2016 Nov; 101(11):1407-1416. PubMed ID: 27662011
[TBL] [Abstract][Full Text] [Related]
2. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
3. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
4. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
Shimomura Y; Hara M; Katoh D; Hashimoto H; Ishikawa T
Ann Hematol; 2018 Jun; 97(6):1049-1056. PubMed ID: 29455235
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
Alchalby H; Zabelina T; Stübig T; van Biezen A; Bornhäuser M; Di Bartolomeo P; Beelen D; Cahn JY; Dreger P; Schroyens W; de Witte T; Olavarria E; Kröger N;
Biol Blood Marrow Transplant; 2014 Feb; 20(2):279-81. PubMed ID: 24201159
[TBL] [Abstract][Full Text] [Related]
6. [Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].
Fujishima M; Fujishima N; Kitadate A; Guo Y; Watanabe A; Ubukawa K; Nara M; Yoshioka T; Kameoka Y; Takahashi N
Rinsho Ketsueki; 2017; 58(7):743-748. PubMed ID: 28781268
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Ayuk F; Kröger N
Bone Marrow Transplant; 2016 Sep; 51(9):1223-7. PubMed ID: 27088376
[TBL] [Abstract][Full Text] [Related]
8. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
11. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Polverelli N; Hernández-Boluda JC; Czerw T; Barbui T; D'Adda M; Deeg HJ; Ditschkowski M; Harrison C; Kröger NM; Mesa R; Passamonti F; Palandri F; Pemmaraju N; Popat U; Rondelli D; Vannucchi AM; Verstovsek S; Robin M; Colecchia A; Grazioli L; Damiani E; Russo D; Brady J; Patch D; Blamek S; Damaj GL; Hayden P; McLornan DP; Yakoub-Agha I
Lancet Haematol; 2023 Jan; 10(1):e59-e70. PubMed ID: 36493799
[TBL] [Abstract][Full Text] [Related]
12. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
15. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
16. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):345-54. PubMed ID: 17317588
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
18. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.
Min CK; Kim DW; Lee JW; Min WS; Kim CC
Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of autologous peripheral blood stem cells mobilized using GM-CSF for acute leukemia with myelofibrosis.
Mehta J; Powles RL; Shepherd V; Dainton M; Treleaven J
Leuk Lymphoma; 1993 Sep; 11(1-2):157-8. PubMed ID: 8106067
[TBL] [Abstract][Full Text] [Related]
20. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
